ArticleJACC. Case reports2026
High-Risk Valve-in-Valve TAVR With Chronic Type B Aortic Dissection.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve replacement (TAVR) is a challenge in patients with chronic aortic dissection given risk of intraoperative dissection extension. There are limited prior case reports. CASE SUMMARY: A 45-year-old man with a history of repaired type A dissection and aortic valve replacement with residual type B dissection presented in cardiogenic shock due to severe prosthetic valve stenosis. Because of his surgical risk and rapid decompensation, a valve-in-valve TAVR was successfully performed, followed by resolution of cardiogenic shock. DISCUSSION: We demonstrate a successful valve-in-valve TAVR in a patient with known type B dissection in the setting of hemodynamic deterioration. TAKE-HOME MESSAGES: TAVR is uniquely challenging in patients with type B aortic dissection but is feasible in the acute setting. Femoral access requires special attention to ensure entry into the true lumen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.